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Lung cancer is a major contributor to overall cancer mortality. Detecting lung cancer while it is still
a localized process is a long-cherished goal for improving the outcome of this disease. Recent
developments suggest that we are approaching this capability. We next have to think about how
to implement a change in our approach to lung cancer management to derive the benefit of
better detection capability. This is an area in which our growing understanding of lung cancer
biology is providing clues on improving the inhibition of cancer progression. Environ Health
Perspect 105(Suppl 4):935-939 (1997)
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Lung cancer is the most frequently fatal
malignancy in much of the developed
world and is the leading cause of cancer
death for both genders in the United
States (1). Significant progress in reducing
lung cancer has not occurred despite
decades of sustained intensive clinical
research efforts. This legacy has forced a
reconsideration of fundamental strategies
by which to approach this cancer (2).
Primary prevention efforts to reduce the
number of children beginning to smoke
and measures to encourage current
smokers to stop smoking are the most
efficient approaches to deal with lung
cancer. Unfortunately, current and former
smokers all have an increased risk ofdevel-
oping lung cancer compared to those who
have never smoked. So for the over 90
million current and former smokers in
the United States alone, more than pri-
mary prevention efforts are required. For
the last 20 years there has been only a
minimal research effort to develop better
approaches to early lung cancer detection.
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Recent developments with molecular
diagnostic techniques to elucidate the
preclinical phase of this disease provide a
basis for optimism in significantly improv-
ing the early detection of lung cancer.
Systematic evaluation of the process of
developing an early detection approach is
useful in highlighting the critical issues
that must be resolved in the evolution of
population-based cancer management.
General Considerations
Lung cancer is the result of chronic
carcinogen exposure to a range of normal
respiratory epithelial cell populations. The
many histologies oflung cancer reflect this
complicated biology (3). Currently, the
precise sequence ofgenetic events leading
to the development ofan invasive cancer is
speculative. We know that a variety ofcar-
cinogens can interact with any ofthe nor-
mal cell populations found in the bronchial
epithelium. Depending on the carcinogen
exposure and the host's ability to handle
xenobiotic injury, the natural history ofthe
cancer will vary. Effective strategies for
early lung cancer detection must reconcile
these realities. Another aspect ofthis chal-
lenge is that the probability ofdeveloping a
lung cancer in the general population is
typically less than 0.001%. Defining popu-
lations with higher risks ofdeveloping lung
cancer improves the prospects for successful
application ofthe diagnostic and simplifies
clinical trials to validate the effectiveness of
early detection tools. Using what we know
today about defining high-risk populations,
we can only improve the a priori chance of
developing cancer by an order of magni-
tude. The down side of using higher risk
populations for marker validation is that
such populations are different from the
actual screening situation that would be
encountered in the general population.
Concentrating on high risk populations
also implies accepting that some cancers
occurring in low-risk populations may not
be detected. As with any other public
health effort, the strategy for evaluating for
lung cancer must be validated carefully. A
priority for screening approaches is to
ensure that sensitivity ofthe process is high
while the cost of screening is reasonable.
Currently, these are complicated calcula-
tions. Beyond the issue ofdirect assay costs,
the direct and indirect cost of the clinical
consequences associated with false negative
and false positive assay determinations is
significant. In developing population
screening approaches for cancer detection,
it is critical to educate the general public
about the goals and nature ofthis type of
research. During the early stages in the
development ofearly cancer detection tech-
nology there will be problems. Examples of
this are currently evident with prostate spe-
cific antigen screening for prostate cancer,
where the risk:benefit aspects of this early
detection effort are controversial (4).
Society's ultimate benefit from compre-
hensive early cancer detection results will
only be achieved through systematic
refinement ofthis and related technologies
over manyyears.
Howto Screen Relevant
Epithelial Samples
for Early Lung Cancer
Inherent to an early lung cancer detection
approach is the requirement to identify the
disease before the development ofmetasta-
tic disease. Because metastatic disease is not
curable, detection at this stage would only
lead to at best a lead-time bias and not a
real improvement in cancer-related survival.
To detect the process in the earlystage, it is
logical to look at the process initiation
site-the respiratory epithelium. This site
can be directly sampled with fiberoptic
bronchoscopy or with a sputum specimen.
Finding evidence of intrabronchial cancer
with bronchial-derived specimens does not
exclude the presence of extrathoracic
metastatic involvement. In theory, the
respiratory compartment would have
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evidence of cancer activity for many years
before the development of metastatic dis-
ease. To avoid detection ofadvanced-stage
lung cancer, the search for the early stage
oflung cancer must start years before the
study population approaches the peak age
ofincidence for the disease. Because chronic
smoking can cause irreversible genetic
damage to epithelial cells, the risk ofmani-
festing a cancer is lifelong. The appropriate
frequency of serial evaluation in high-risk
populations must be formally defined with
clinical studies.
What Markers to Use
The dominant question regarding early
lung cancer detection is what marker or
combination of markers should be used to
detect all lung cancer. To facilitate this
marker selection process, we adapted the
functional classification of the lung into
three regions. These groups are based on
the shared biology of the proximal, mid-
zone, and distal lung (5). For example, the
proximal lung shares the biological response
to injury ofsquamous metaplasia. This type
ofepithelium has a range ofdefined differ-
entiation markers including morphology,
cross-linked envelope formation, and par-
ticular cytokeratins. We have previously
proposed lists ofcandidate makers for the
pulmonary compartments as well. A num-
ber ofcritical questions exist in optimizing
early lung cancer detection, including how
to select the most informative ofthe possi-
ble biologic markers and how to determine
the number of markers to be used. In our
experience, the most relevant gold standard
is "what works." We previously published
studies on the use ofarchival sputum speci-
mens derived from an already concluded
clinical trial in which eventual lung cancer
status was known. In a nonconcurrent,
prospective, blinded analysis, we reported
that two immunocytochemical markers
showed a 91% sensitivity, 88% specificity
in determining who would or would not
develop lung cancer (6). This analysis was
performed on serial sputum specimens
obtained annually during the course of a
chest X-ray and conventional sputum cytol-
ogy study. From the known clinical follow-
up information, it was established that the
90% accuracy (80% positive predictive
value and 94% negative predictive value in
the 62 evaluable cases) in predicting lung
cancer status was achieved on average 20
months prior to routine clinical detection.
Presumably the two monoclonal antibodies
are detecting cellular targets that reflect
ongoing carcinogenesis.
We recently mapped the expression of
the more useful of the two immunocyto-
chemical markers (703D4). We used lung
tissues from surgical blocks in which we
had determined the morphology in the
nonneoplastic epithelial compartments sur-
rounding a resected primary lung cancer
(7). This is an exercise in studying field car-
cinogenesis biology. The pattern ofantigen
expression in tissues that have had chronic
carcinogen exposure may define cellular
populations ofparticular importance in
identifying other useful early detection
markers. We are keeping the conserved ele-
ments ofepithelial biology as a central focus
forearlylung cancer detection approaches.
Using this same strategy and also the
same sputum archival specimens from the
Johns Hopkins studies (6), investigators
from Johns Hopkins reported that deter-
mination ofa ras mutation in sputa identi-
fied individuals who would go on to
develop lung cancer (8). Other trials with
this strategy are in progress and potentially
will provide new clinical/pathologic
archival resources to define the true utility
ofadditional markers (9).
Selecting a Marker
for Clinical Early
Detection Validation
A major developmental requirement for a
proposed early detection tool is to estab-
lish a robust, sensitive, reproducible, effi-
cient assay format (10). We have worked
to standardize the handling of bronchial
lavage fluids to permit specimen conserva-
tion. The goal is to perform a range of
assays on small samples of bronchial
epithelial cells (11). Early in the process of
marker selection, the precision of a pro-
posed biomarker assay must be optimized
and standardized. Due to the inherent
complexity ofdetecting all the biology of
the different forms oflung cancer, it may
be necessary to use a panel of markers.
This will provide more information in
determining the status of the bronchial
epithelium undergoing the carcinogenesis.
Rather than relying exclusively on the
expression ofa single marker, therefore, the
pattern ofexpression ofa battery ofmark-
ers would be evaluated. Representative
component markers could include markers
of genetic damage such as particular
microsatellite probes, markers ofcell prolif-
eration, and expression ofgrowth factors or
their receptors. Validation studies ofpartic-
ular biomarker panels with relevant
archival material from individuals with
known clinical outcomes could establish
with defined statistical precision which
markers are most informative as early
detection probes.
Technological Developments
Relevant to Population-based
Screening
In the current cost-sensitive environment,
an efficient and economical assay is required.
Over the next decade, progress in comput-
erization and microchip-based technology
may revise current concepts ofpopulation-
based screening. These experimental assay
formats for gene probes may enable the
throughput of large assay numbers. This
technology will enable validating pilot tri-
als to determine which assays provide the
kind of clinically useful information that
wouldjustify population-based application.
These assays will be multiplexed so that a
number ofprobes will be analyzed simulta-
neously, providing sufficient biological
information to sort through the compli-
cated biological issues already discussed.
Recent developments with microchip-
based assays suggest that this technology
will be a more economical assay platform
on which to accomplish molecular analysis
ofmany clinical specimens. Refinements in
several technologies have contributed to
this possibility. The use of microjet tech-
nology accomplishes the precise, repro-
ducible deposition of target nucleotide
probes on a test matrix. Nucleotide probes
that have been formulated to orient opti-
mally for hybridization are sprayed on a
silicon surface. Using microelectronic cir-
cuitry, surface charges are modified to
allow reagent exposure, probe hybridiza-
tion, and disruption oflowaffinity binding
interactions (12,13). A variety of biotech-
nology companies have pioneered different
approaches to this technology (14).
Another enabling aspect of this
technology is an efficient detection system.
Collaborators from the Genosensor
Consortium developed an integrated
charge-coupled detector (12). This consor-
tium included members from industry and
academe with support from the Advanced
Technology Program (Gaithersburg, MD)
and the National Center for Human
Genome Research (Bethesda, MD). A
charge-coupled device has been developed
that detects photons or radioactive decay
products at pixel locations where the sam-
ple has bound to complementary probes.
The number ofelectrons is calibrated to be
proportional to the number of molecular
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binding events in that area so that
quantitative information can be obtained.
Because ofsilicon's sensitivity to electromag-
netic fields, this matrix material is a favor-
able medium. The abundance ofsilicon
means that the cost ofusing this material as
a matrix is slight, which is an essential
design consideration for population-based
screening applications.
The enthusiasm for this molecular
diagnostic platform is growing but this
new family ofmolecular diagnostics must
be carefully validated. First, the specificity
and reproducibility ofthis approach must
be established in model systems. Next, the
level of sensitivity must be optimized to
ensure signal detection in clinically relevant
specimens. The current generation ofbio-
sensor assays may not include polymerase
chain reaction amplification steps. Whether
informative markers can be monitored
within the existing range ofdetection with
direct hybridization remains to be estab-
lished. The necessity ofa signal amplifica-
tion step would significantly increase the
complexity and the cost of these proce-
dures. Therefore, all the specimen-han-
dling procedures must be optimized to
prevent clinical specimen loss. At least ini-
tially in assay development, the focus must
be on abundantly expressed target mole-
cules. Innovative strategies to recover epi-
thelial cells from clinical specimens are
being considered to increase the information
obtained by these techniques.
Ultimately, the information provided by
these automated, robotically driven assays
will include many molecular probes ana-
lyzed on serial clinical specimens obtained
during large clinical trials. Because this tech-
nology evaluates multiple genetic markers at
once, systematic clinical investigation will be
required to discern the most informative
markers for inclusion in a detection panel.
The potential information load generated
with this type oftechnology will soon be
overwhelming. Developing rigorous epi-
demiological and biometric approaches for
optimal management and retrieval ofinfor-
mation contained in such data sets will be
instrumental in revealing directions for
continuing improvement in this technology.
Rational Interventions
for Early Lung Cancer
Assuming that the feasibility ofpopulation-
based screening continues to improve, the
critical need then becomes to complement
this positive diagnostic development.
Effective epithelial-directed interventions
that arrest the early phase oflung cancer
must be defined. Fortunately, the study of
cancer chemoprevention is rapidly develop-
ing (15). Recent studies ofchemopreven-
tion using 5-carotene have pointed out the
complexity ofthis approach. f-Carotene is
a precursor of vitamin A and it was
assumed that the oral supplementation of
this compound would lead to a replace-
ment of deficient vitamin A stores and
potentially reduce cancer frequency
(16-18). These n-carotene chemopreven-
tion trials have not shown any benefit and
raise the question ofwhether they may
cause harm. An unexpected frequency of
lung cancer occurred in two of the three
intervention trials for the group ofsubjects
receiving 5-carotene. This experience
suggests the importance of understanding
the underlying biology ofthe intervention.
The biosynthesis of vitamin A can be
impaired under certain circumstances, as
with heavy alcohol ingestion (19). Whether
random events or an unanticipated factor,
such as an imbalance in the accrual of
subjects with heavy alcohol consumption,
contributed to the unexpected finding
may never be absolutely determined.
However, the preclinical information
about retinoid chemoprevention is much
more extensive than was the rationale for
the use of ,B-carotene. In contrast to the
5-carotene experience, retinoids have been
shown to significantly reduce the frequency
of second primary cancers of the upper
aerodigestive tract, including lung cancer
(15,20). The frequency ofside effects with
13-cis-retinoic acid as a chemoprevention
agent-including headache, mouth sores,
itchiness, and hyperlipidemia-has reduced
enthusiasm for this experimental approach.
We recently reported that 13-cis-retinoic
acid binds to albumin and is significantly
less bioactive in that state (21). In another
recently reported study, French investiga-
tors found that intracellular levels of all-
trans retinoic acid best correlate with
patients in complete remission of their
acute promyelocytic leukemia (22). This
was supported in part by the finding that
the leukemic cells from patients clinically
resistant to trans retinoic acid were still
sensitive to low dose all-trans retinoic acid
in vitro. From this experience, they also
conclude that bioavailability of retinoic
acid to target cell populations is a major
barrier to therapeutic benefit. To optimize
the availability ofretinoic acid to the trans-
formed bronchial epithelial cells, an
aerosolized drug delivery approach may be
required. This direct epithelial delivery
would not only increase the bioavailability
of the retinoid to the target bronchial
epithelial cells but also would decrease the
potential for systemic toxicity. We propose
to evaluate this approach clinically.
Another intervention approach that
arises from consideration of the tumor
biology oflung cancer involves arachidonic
acid metabolism. This pathway may be
involved in the signal transduction oflung
cancer growth factors. We have identified
the enzyme 5-lipoxygenase as playing a key
role in cell signaling because this pathway
appears to be activated by two important
lung cancer-associated autocrine growth
factors (23). Insulinlike growth factor-I
(IGF-I) and gastrin releasing peptide both
cause prompt elevation in the production
ofa specific 5-lipoxygenase dependent cell
product, 5-HETE. We found low concen-
trations of 5-HETE stimulate the growth
of lung cancer cell lines in serum-free
media. Using several inhibitors that block
the lipoxygenase pathway through different
mechanisms, a consistent growth reduction
is observed for most lung cancer cell lines.
In both in vitro and in vivo conditions, the
exposure of the lipoxygenase inhibitors to
the lung cancer cell lines results in an
increase ofapoptotic cells.
We propose the following model to
explain these findings: The role of auto-
crine growth factors in lung biology may
be to function as promotion factors. We
postulated that chemoprevention strategies
based on neutralizing the effects of
autocrine growth factors could be valuable
in arresting tumor promotion (24). For
this reason, we are evaluating the use of
lipoxygenase inhibitors as an intervention
strategy to control early cancer progression.
This approach is summarized in Figure 1.
Ifwe think about carcinogenesis as a dys-
regulation ofnormal cellular homeostasis,
Figure 1. Schematic representation of the dysregula-
tion central to epithelial carcinogenesis. The cancer cell
develops the ability to circumvent normal regulatory
control.
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we see that the malignant cell has devised
a way to circumvent growth regulation.
Such a shunt may be sustained through the
action of constitutive activation of an
IGF-I receptor circuit, as suggested by
Baserga (25). The action ofthe lipoxyge-
nase inhibitor eliminates the shunt and
permits the reestablishment ofnormal cel-
lular regulation, leading to normal differ-
entiated functions. The most important
normal cellular pathway that is reexpressed
after lipoxygenase inhibition may be apop-
totic cell regulation. The most important
role ofa tumor-promotion factor such as
the activators ofthe IGF receptor may be
to protect the clonally expanding early
cancer from apoptotic clearance. New
information is rapidly expanding our
appreciation of the importance of the
control of cell division relative to the
process ofcancer (26). Understanding cell
cycle regulation has implications for both
early detection and intervention research.
A new paradigm for translational approaches
to lung cancer intervention is summarized
in Figure 2. Ifwe can identify, at an early
stage in carcinogenesis, critical tumor
promotion factors that thwart normal
cell-cycle regulation, neutralizing the stim-
ulatory effect of those factors would
potentially allow the regulatory effect of
apoptosis to be reestablished. Candidate
agents to be evaluated for this type of
approach include inhibitors of cyclo-
oxygenase protein kinase C and other crit-
ical signal-transduction molecules. This
strategy forms a blueprint for the future.
Coordinated research involving molecular
Model of Blocktumor
carcinogenesis promoter
Tumor r promoter pr,er
/,Apoptosis-- _ *p Apoptosis
Proliferation Proliferation
Figure 2. Proposed strategy for cancer intervention
approaches. By neutralizing factors allowing the cancer
cell to escape cell cycle regulation, apoptotic clearance
of neoplastic cells can be reexpressed.
detection ofearly epithelial phase carcino-
genesis with the use ofdefined molecular
antagonists that upregulate apoptosis is
emerging as a promising strategy to
improve lung cancer mortality.
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